GL1X · GenesisL1 explorer

Research workbench

Closed state of pre-fusion SARS-cov-2 kappa variant spike protein

Analyse Closed state of pre-fusion SARS-cov-2 kappa variant spike protein in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7SBP
Type
protein
Length
3,330 residues
Chains
3
Method
electron microscopy
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Spike glycoprotein
UniProt
P0DTC2
Ligands
NAG, MAN, FUC
Pockets
20 · best druggability 0.86

Structure

electron microscopy · 1 distinct chain · 23% helix, 32% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, CSpike glycoproteinprotein111023% helix, 32% strandP0DTC2

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 93 copies · chains A, C, B
  • MAN · alpha-D-mannopyranose · sugar · 27 copies · chains C, A, B
  • FUC · alpha-L-fucopyranose · sugar · 3 copies

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

20 pockets found on a 1 Å grid, 20 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110440.860.87131empty
25360.830.8953empty
310910.830.84117empty
42830.820.9337empty
52760.810.9341empty

Interfaces

3 interfaces between chains.

  • A–B · 6570 Ų buried · 55 hydrogen bonds · protein-protein
  • A–C · 6456 Ų buried · 63 hydrogen bonds · protein-protein
  • B–C · 6342 Ų buried · 51 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 57 glycan, 45 disulfide (N-glycosylation, disulfide).

Compared structures

  • 7SBP · Closed state of pre-fusion SARS-CoV-2 Kappa variant spike protein · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.